

Author(s): Seetha Monrad, M.D., 2009

License: Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution–Noncommercial–Share Alike 3.0 License:** <http://creativecommons.org/licenses/by-nc-sa/3.0/>

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.



Crystalline Arthritis

November 30, 2009

Seetha Monrad M.D.
Division of Rheumatology
Department of Internal Medicine

Learning Objectives

1. Understand the metabolism and renal handling of uric acid
2. Know the common causes of hyperuricemia
3. Understand the relationship between uric acid and gout
4. Describe the typical presentations of the different stages of gout
5. Know the treatment modalities for the different stages of gout
6. Describe the spectrum of disease associated with calcium pyrophosphate depositions
7. Describe the differences between gout and pseudogout

Supplementary references:

1. Feig, DI, et al. "Uric acid and cardiovascular risk". *N Engl J Med*. 2008 Oct 23;359(17):1811-21.
2. Teng, GG, et al. "Pathophysiology, clinical presentation and treatment of gout." *Drugs* 2006;66(12):1547-63.